Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
04:15am, Saturday, 06'th Jul 2024
Vertex has built an empire from cystic fibrosis treatment, generating billions of dollars in annual revenue. The company is set to dominate the market through the late 2030s -- and possibly beyond.
The 3 Best Biotech Stocks to Buy in July 2024
02:14pm, Friday, 05'th Jul 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
07:45am, Friday, 05'th Jul 2024
Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities.
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
05:45am, Friday, 05'th Jul 2024
Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
05:50am, Thursday, 04'th Jul 2024
Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.
3 Top-Rated Gene Editing Stocks Actually Making Money
03:11pm, Wednesday, 03'rd Jul 2024
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
10:15am, Wednesday, 03'rd Jul 2024
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
06:24am, Tuesday, 02'nd Jul 2024
One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.
3 Breakout Biotech Stocks on Track to Double by 2032
10:02am, Monday, 01'st Jul 2024
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
09:30am, Monday, 01'st Jul 2024
If you have some cash on hand to invest long term, there are plenty of stocks begging to be bought. Vertex expects several product launches even as its mainstay portfolio continues to drive profitabil
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
07:45am, Friday, 28'th Jun 2024
The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also plan
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
05:50am, Friday, 28'th Jun 2024
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
2 Healthcare Stocks That Are Screaming Buys in June
03:31am, Friday, 28'th Jun 2024
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and pr
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
10:55am, Thursday, 27'th Jun 2024
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
08:41am, Thursday, 27'th Jun 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
